Graffinity and Amgen enter into drug discovery research agreement

28-Feb-2007

Graffinity Pharmaceuticals GmbH announced that it has entered into a research collaboration with Amgen. Under the terms of the agreement, Graffinity will receive technology access fees and success payments for the generation of novel small molecule hits against a broad range of drug targets. Amgen will gain access to Graffinity's proprietary fragment-based drug discovery technology which uses chemical microarrays to screen for small molecule fragments that bind to a variety of drug targets which play a key role in major human diseases. The identification of novel modes of action and chemistry is a major focus of the collaboration. Financial details of the transaction were not disclosed.

Other news from the department business & finance

Most read news

More news from our other portals

Under the magnifying glass: The world of microscopy